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Graves-Basedow disease (GBd) since late fifties has been
considered to be autoimmune thyroid disorder where the
presence of thyroid stimulating antibodies (TSAb) may
lead to hyperthyroidism, thyroid orbitopathy and thyroid
dermopathy. During last years it was generally accepted
that development of Graves-Basedow disease is dependent
on the presence of two or three groups of factors - genetic
and environmental or genetic, environmental and endo-
genous. Familial clustering of GBd, familial presence of
thyroid autoantibodies and high concordance in the inci-
dence and clinical course of the disease in monozygotic
siblings all suggested that several genes decide about sus-
ceptibility to this disorder and likely its phenotypes. On
the other hand environmental agents and endogenous fac-
tors served as triggers important to the development of
the disease, its clinical course and response to given ther-
apy. It was believed that finally, development of GBd (and
other autoimmune disorders) is a consequence of lack of
balance between the formation of self reactive T cells and
central and peripheral tolerance. As a result thyroid was
infiltrated by self reactive T cells that in turn affected
B cells and led to the production of thyroid stimulating
antibodies.
Most recently etiopathogenesis of GBd became further
complicated by both clinical and molecular findings. First,
GBd can be clinically presented as a hypothyroidism
depending on the switch of TSAb production to thyroid
blocking antibody (TBAb) production as well as vice versa.
Some findings suggest that in prone classically hyperthyr-
oid patient the administration of methimazole can provoke
switch off of TSAb generation and start of TBAb followed
by block of thyroid hormones biosynthesis and quite rapid
morphological damage of thyroid cells. It is a pity that in
other hypothyroid patient administration of thyroxine can
switch on the generation of TSAb and switch off the pro-
duction of TBAb. Second, it is more and more obvious
that autoimmune thyroid disorders and differentiated
thyroid cancer (DTC) especially of papillary type (PTC)
share some genetic factors (RET/PTC1) and environmen-
tal and epidemiological features. In addition presence of
GBd disease in patients with DTC leads to increased mor-
tality of cancer patients. Third, microarray DNA analysis
of thyroids from GBd patients with severe course of the
disease led to the identification of seven additional genes
either overexpressed or underexpressed that may be
responsible for high level of TSH-R Abs, large goiter size
and high free T3/free T4 ratio, features characteristic for
patients that poorly respond to anti-thyroid drug therapy.
In addition to these clinical observations, the pathogenesis
of GBd during the last two-three years was strongly
affected by studies suggesting that non sufficient periph-
eral tolerance was a key to autoimmunity in general,
including mechanisms leading to development of Graves-
Basedow disease. In a way we returned to Volpe hypoth-
esis developed in the 70-ies of the previous century that
pointed out the role of T-suppressor cells. At present the
name suppressor cells was postponed and we know that
control of self reactive T cells is a function of T regulatory
cells (Tregs). It has been proven that block of activation of
Tregs both in experimental animals and humans led to
the development of generalized fatal autoimmunity. The
mechanism of appropriate Tregs activation concerning
first signal (MHC-TCR) and especially second costimula-
tory signals (CD28-B7-1(CD80) or CD28-B7-2 (CD86))
will be presented and their role for the thyroid autoimmu-
nity discussed. The progress in our knowledge concerning
autoimmunity as a whole and GBd as a thyroid autoim-
mune disorder clearly shows that pathogenesis of this
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disorder is more complex than previously expected and
that personalized approach to given patient based on clini-
cal and molecular findings is more important than the
hope that single finding (light in corridor) brings a positive
solution for all patients with Graves-Basedow disease.
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